Northwestern University

University of Illinois

Illinois Institute of Technology

University of California

Anthony J Schaeffer

David J Klumpp

Praveen Thumbikat

Charles N Rudick

Ophir Frieder

Bryan White

Benjamin Kyle Billips

Stephen F Murphy

Joseph Done

Alisa E Koch

JoEllen L Westropp

Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprisinglipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune—(e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

Lipotechoic acid for immune modulation

Provided herein are compositions and methods for the treatment of conditions such as benign prostatic hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), chronic prostatitis (CP) and/or chronic pelvic pain syndrome (CPPS). In particular, provided herein are combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist.

Combination mast cell inhibition for treatment of BPH/LUTS

Provided are methods for treating acute and recurring urinary tract infections in dogs.

Methods of treating dog urinary tract infections

Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprisinglipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune- (e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g.,, and). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from, and).

Altered microbiome of chronic pelvic pain

The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.

Compositions and methods for treatment of pain

The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity.

Live-attenuated compositions for bacterial infections

The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1&#x3b1;) to treat or prevent chronic pelvic pain syndrome.

Treatment of chronic pelvic pain syndrome

The present invention provides methods and compositions for treating chronic pelvic pain syndrome. In particular, the present invention provides methods and compositions for treating chronic pelvic pain syndrome with an agent that targets MCP-1, MIP-1&#x3b1;, or the CCR-2 receptor.

Methods for treating chronic pelvic pain syndrome

Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A

The present invention provides biomarkers of chronic pelvic pain syndrome for use in diagnosis, drug screening, therapy monitoring, research and therapeutic applications. In particular, the present invention provides MCP-1 and MIP-1&#x3b1; as biomarkers of chronic pelvic pain syndrome.

Biomarkers of chronic pelvic pain syndrome

A method for the construction and utilization of a medical records system capable of providing a continuous data stream of epidemiological data to the records system via kits provided to the symptomatic population to obtain and record an epidemiological profile in a searchable database by applying data mining or automated intelligence techniques whereby, when a valid epidemiological profile is established in the database, automated diagnosis and prescription of treatment may be had for patients presenting similar symptoms. Knowledge discovery techniques may further operate on the database to provide suggested courses of treatment for a virtual class of patients, epidemic threat awareness, and knowledge of drug resistance mutations by a pathogen without direct query of the database.

Growing community of inventors

Chicago, IL, United States of America

Anthony J Schaeffer